Anaprazole

Phase 3Small molecule

SSihuan Pharmaceutical Holdings Group Ltd.

Anaprazole is one of 64 small molecule programs targeting Duodenal Ulcer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Duodenal UlcerActive, not recruiting

EsophagitisActive, not recruiting

Duodenal UlcerPhase 3

Active, not recruiting

EsophagitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

54 competitors in Esophagitis

#DrugCompanyPhaseTrials

Prevacid

Takeda

Approved

18 2

Dexilant

Takeda

Approved

4 3

Nexium

DDexcel Pharma Technologies Ltd.

Approved

14 4

Flovent

GSK

Approved

1 5

Aciphex

Akero Therapeutics

Approved

2 6

Pulmicort

SSalix

Approved

1 7

Protonix

WWyeth-Lederle Vaccines

Approved

1 8

Mucosta

Otsuka

Approved

1 9

Esomeprazole Mg

AstraZeneca

Approved

1 10

Alka-Seltzer

AAbbott

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalNot yet recruiting

Tics

NCT07345689

Clinical

Trials by Indication[1]

Duodenal Ulcer2 trials

A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.

Completed·SSihuan Pharmaceutical Holdings Group Ltd.·Phase 2·NCT04503629·150 enrolled

A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.

Unknown status·SSihuan Pharmaceutical Holdings Group Ltd.·Phase 3·NCT04215653·448 enrolled

Interaction1 trial

Pharmacokinetic Interactions of Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth

Unknown status·SSihuan Pharmaceutical Holdings Group Ltd.·Phase 1·NCT04444011·32 enrolled

Tics1 trial

A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations

Not yet recruiting·XXuanzhu Biopharmaceutical Co., Ltd.·Phase 4·NCT07345689·60 enrolled

Single Ascending Dose1 trial

A Single Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects

Completed·SSihuan Pharmaceutical Holdings Group Ltd.·Phase 1·NCT04467060·74 enrolled

Esophagitis1 trial

A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis

Unknown status·XXuanzhu Biopharmaceutical Co., Ltd.·Phase 2·NCT05604261·156 enrolled

1 more indication

Unspecified3 trials

A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects

Completed·SSihuan Pharmaceutical Holdings Group Ltd.·Phase 1·NCT04466748·36 enrolled

A Multiple Ascending High Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects

Completed·SSihuan Pharmaceutical Holdings Group Ltd.·Phase 1·NCT04471922·45 enrolled

Food Effect Study of Anaprazole in Healthy Chinese Subjects

Completed·SSihuan Pharmaceutical Holdings Group Ltd.·Phase 1·NCT04463173·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Anaprazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anaprazole compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anaprazole. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sihuan Pharmaceutical Holdings Group Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSihuan Pharmaceutical Holdings Group Ltd.

Anaprazole

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Duodenal Ulcer2 trials

Interaction1 trial

Tics1 trial

Single Ascending Dose1 trial

Esophagitis1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News